home All News open_in_new Full Article

Rakovina Therapeutics Announces Debentureholder Approval of Debenture Extension, Expiry of Warrant Incentive Program

VANCOUVER, British Columbia, Nov. 28, 2025 (GLOBE NEWSWIRE) — Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV)(FSE: 7JO0) a biopharmaceutical company advancing cancer therapies through AI-enabled drug discovery, announces that further to its news release dated June 30, 2025, and in accordance with the terms of a debenture indenture (the “Indenture”) between the Company […]


today 7 d. ago attach_file Other

attach_file Events
attach_file Science
attach_file Culture
attach_file Economics
attach_file Politics
attach_file Other
attach_file Other
attach_file Economics
attach_file Economics
attach_file Other
attach_file Politics
attach_file Events
attach_file Economics
attach_file Economics
attach_file Other
attach_file Transport
attach_file Other
attach_file Economics
attach_file Economics
attach_file Events


ID: 3417505723
Add Watch Country

arrow_drop_down